Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: Development of antagonists with increased potency and receptor selectivity

Peptides

Volumn 23, Issue 10, 2002, Pages 1817-1827

  Brauns, Olaf ^a   Brauns, Simone ^a   Jenke, Marc ^a   Zimmermann, Bodo ^a   Dautzenberg, Frank M ^b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b Gewerbestrasse 16   (Switzerland)

Author keywords

Antagonist; Antisauvagine; CRF; CRF receptor; Sauvagine

Indexed keywords

ANTISAUVAGINE 30; CORTICOTROPIN RELEASING FACTOR 2B RECEPTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR[12-41]CYCLO(30-33)[12 DEXTRO PHENYLALANINE 21,38 NORLEUCINE 30 GLUTAMIC ACID 33 LYSINE]; CYCLIC AMP; SAUVAGINE[10-40][11 DEXTRO PHENYLALANINE 12 HISTIDINE 21,23 ALANINE 22 ARGININE]; SAUVAGINE[10-40][11 TYROSINE 12 HISTIDINE 17 NORLEUCINE]; SAUVAGINE[10-40]CYCLO(29-32)[11 DEXTRO PHENYLALANINE 12 HISTIDINE 17 NORLEUCINE 29 GLUTAMIC ACID 32 LYSINE]; SAUVAGINE[10-40]CYCLO(29-32)[11 TRYPTOPHAN 12 HISTIDINE 17 NORLEUCINE 29 GLUTAMIC ACID 32 LYSINE]; UNCLASSIFIED DRUG; LACTAM; PEPTIDE FRAGMENT;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYCLIZATION; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; PEPTIDE SYNTHESIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL; BINDING COMPETITION; CELL LINE; CHEMISTRY; CIRCULAR DICHROISM; DRUG ANTAGONISM; ENZYME SPECIFICITY; METABOLISM; MOUSE; PROTEIN MOTIF; RAT;

ARA;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BINDING, COMPETITIVE; CELL LINE; CIRCULAR DICHROISM; CYCLIC AMP; HUMANS; LACTAMS; MICE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0036803440     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00139-0     Document Type: Article

References (39)

1. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160:1999;1-12.
2. Assil I.Q., Shomali M.E., Abou-Samra A.B. An oxidation resistant radioligand for corticotropin-releasing factor receptors. Peptides. 22:2001;1055-1061.
3. Beyermann M., Fechner K., Furkert J., Krause E., Bienert M. A single-point slight alteration set as a tool for structure-activity relationship studies of ovine corticotropin releasing factor. J. Med. Chem. 39:1996;3324-3330.
4. Böhm G. Quantitative analysis of protein far UV circular dichroism spectra by neural networks. Protein Eng. 5:1992;191-195.
5. Brauns O., Liepold T., Radulovic J., Spiess J. Pharmacological and chemical properties of astressin, antisauvagine-30 and α-helCRF: significance for behavioral experiments. Neuropharmacology. 41:2001;507-516.
6. Brauns O, Brauns S, Zimmermann B, Jahn O, Spiess J. Differential responsiveness of CRF receptor subtypes to N-terminal truncation of peptidic ligands. Peptides 2002;23:881-8.
7. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc. Natl. Acad. Sci. U.S.A. 90:1993;8967-8971.
8. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:1973;3099-3108.
9. Collantes E.R., Dunn W.J. 3rd Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues. J. Med. Chem. 38:1995;2705-2713.
10. Dathe M., Fabian H., Gast K., Zirwer D., Winter R., Beyermann M.et al. Conformational differences of ovine and human corticotropin releasing hormone. A CD, IR, NMR and dynamic light scattering study. Int. J. Pept. Protein Res. 47:1996;383-393.
11. Dautzenberg F.M., Dietrich K., Palchaudhuri M.R., Spiess J. Identification of two corticotropin-releasing factor receptors from Xenopus laevis with high ligand selectivity: unusual pharmacology of the type 1 receptor. J. Neurochem. 69:1997;1640-1649.
12. Dautzenberg F.M., Kilpatrick G.J., Hauger R.L., Moreau J.L. Molecular biology of the CRH receptors - in the mood. Peptides. 22:2001;753-760.
13. Dautzenberg F.M., Py-Lang G., Higelin J., Fischer C., Wright M.B., Huber G. Different binding modes of amphibian and human CRF type 1 and type 2 receptors: evidence for evolutionary differences. J. Pharmacol. Exp. Ther. 296:2001;113-120.
14. Dautzenberg F.M., Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23:2002;71-77.
15. Donaldson C.J., Sutton S.W., Perrin M.H., Corrigan A.Z., Lewis K.A., Rivier J.E.et al. Cloning and characterization of human urocortin. Endocrinology. 137:1996;2167-2170.
16. Eckert K., Jahn O., Tezval H., van Werven L., Spiess J. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists. Proc. Natl. Acad. Sci. U.S.A. 98:2001;11142-11147.
17. Gothe R., Seyfarth L., Schumann C., Agricola I., Reissmann S., Lifferth A.et al. Combination of allyl protection and HYCRAM (TM)-linker technology for the synthesis of peptides with problematical amino acids and sequences. J. Prakt. Chem. 341:1999;369-377.
18. Gulyas J., Rivier C.L., Perrin M.H., Koerber S.C., Sutton S.W., Corrigan A.Z.et al. Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10575-10579.
19. Hauger RL, Dautzenberg FM. Regulation of the stress response by corticotropin-releasing factor receptors. In: Conn PM, Freedman ME, editors. Neuroendocrinology in Physiology and Medicine. Totowa: Humana Press, 1999. p. 261-86.
20. 125I -Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors Neuropharmacology. 40:2001;114-122.
21. Hsu S.Y., Hsueh A.J.W. Human stresscopin and stresscopin-related peptide are selective ligands for the corticotropin-releasing hormone receptor. Nat. Med. 7:2001;605-611.
22. Jenkinson D.H. How we describe competitive antagonists: three questions of usage. Trends Pharmacol. Sci. 12:1991;53-54.
23. Kates S.A., Daniels S.B., Albericio F. Automated allyl cleavage for continuous-flow synthesis of cyclic and branched peptides. Anal. Biochem. 212:1993;303-310.
24. Lewis K., Li C., Perrin M.H., Blount A., Kunitake K.S., Donaldson C.J.et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98:2001;7570-7575.
25. Lovejoy D.A., Balment R.J. Evolution and physiology of the corticotropin-releasing factor (CRF) family of neuropeptides in vertebrates. Gen. Comp. Endocrinol. 115:1999;1-22.
26. MacKay D. How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? J. Pharm. Pharmacol. 30:1978;312-313.
27. Marsh I.R., Bradley M., Teague S.J. Solid-phase total synthesis of oscillamide Y and analogues. J. Org. Chem. 62:1997;6199-6203.
28. Miranda A., Lahrichi S.L., Gulyas J., Koerber S.C., Craig A.G., Corrigan A.Z.et al. Constrained corticotropin-releasing factor antagonists with i-(. i+3 ) Glu-Lys bridges J. Med. Chem. 40:1997;3651-3658.
29. Pallai P.V., Mabilia M., Goodman M., Vale W.W., Rivier J.E. Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: circular dichroism and prediction studies. Proc. Natl. Acad. Sci. U.S.A. 80:1983;6770-6774.
30. Reinscheid R.K., Ardati A., Monsma F.J., Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. 271:1996;14163-14168.
31. Reyes T.M., Lewis K., Perrin M.H., Kunitake K.S., Vaughan J., Arias C.A.et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98:2001;2843-2848.
32. Rivier J.E., Rivier C.L., Galyean R., Miranda A., Miller C., Craig A.G.et al. Single point D-substituted corticotropin-releasing factor analogues: effects on potency and physicochemical characteristics. J. Med. Chem. 36:1993;2851-2859.
33. Rivier J.E., Rivier C.L., Vale W.W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science. 224:1984;889-891.
34. Rivier J.E., Kirby D.A., Lahrichi S.L., Corrigan A.Z, Vale W.W., Rivier C.L. Constrained corticotropin releasing factor antagonists (astressin analogues) with long duration of action in the rat. J. Med. Chem. 42:1999;3175-3182.
35. Rühmann A., Bonk I., Lin C.R., Rosenfeld M.G., Spiess J. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc. Natl. Acad. Sci. U.S.A. 95:1998;15264-15269.
36. Rühmann A., Köpke A.K., Dautzenberg F.M., Spiess J. Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10609-10613.
37. Smagin G.N., Heinrichs S.C., Dunn A.J. The role of CRH in behavioral responses to stress. Peptides. 22:2001;713-724.
38. Vale W.W., Vaughan J., Perrin M.H. Corticotropin-releasing factor (CRF) family of ligands and their receptors. The Endocrinologist. 7:1997;3S-9S.
39. Vaughan J., Donaldson C.J., Bittencourt J., Perrin M.H., Lewis K., Sutton S.W.et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature. 378:1995;287-292.